WB
NBIX icon

Webster Bank’s Neurocrine Biosciences NBIX Stock Holding History

Webster Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.72K Sell
28
-4
-13% -$593 ﹤0.01% 575
2026
Q1 		$4.22K Hold
32
– – ﹤0.01% 596
2025
Q4 		$4.54K Hold
32
– – ﹤0.01% 569
2025
Q3 		$4.49K Hold
32
– – ﹤0.01% 565
2025
Q2 		$4.02K Buy
32
+2
+7% +$229 ﹤0.01% 558
2025
Q1 		$3.32K Hold
30
– – ﹤0.01% 543
2024
Q4 		$4.09K Hold
30
– – ﹤0.01% 542
2024
Q3 		$3.46K Hold
30
– – ﹤0.01% 557
2024
Q2 		$4.13K Hold
30
– – ﹤0.01% 565
2024
Q1 		$4.14K Buy
+30
New +$4.1K ﹤0.01% 553

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Webster Bank's NBIX Position: Q2 2026 in Review

Webster Bank reduced its Neurocrine Biosciences (NBIX) stake by 13% in Q2 2026, selling an estimated $593 and leaving 28 shares worth $4.72K. The position accounts for ﹤0.01% of the portfolio, ranked #575.

Webster Bank first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Webster Bank held 28 shares of Neurocrine Biosciences worth $4.72K as of Q2 2026.
  • Webster Bank sold 4 Neurocrine Biosciences shares in Q2 2026, an estimated $593.
  • Neurocrine Biosciences made up ﹤0.01% of Webster Bank's portfolio in Q2 2026, its #575 holding.
  • Webster Bank first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Webster Bank's 13F filing for Q2 2026, filed 20 Jul 2026.